Physician profile
Glenn Stoller
NPI 1558366526
$12,659.03
in general payments reported to CMS, 2019-2025
26 companies · $497 in 2025
The $497 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,723 · 2020: $101 · 2021: $524 · 2022: $501 · 2023: $746 · 2024: $3,567 · 2025: $497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,520 · Food and Beverage: $2,290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,520.00 |
| Food and Beverage | $2,289.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $6,715.61 | 2019-2022 | |
| Genentech USA, INC. | $3,012.54 | 2019-2025 | Vabysmo, Susvimo |
| Apellis Pharmaceuticals, INC. | $531.87 | 2023-2024 | Syfovre |
| Abbvie INC. | $519.39 | 2022-2025 | Ozurdex, Lumigan, Alphagan P |
| Biotissue Holdings INC. | $419.61 | 2019-2024 | |
| Mallinckrodt Hospital Products INC. | $254.03 | 2021-2023 | Acthar |
| Allergan, INC. | $241.04 | 2019-2022 | |
| Harrow Eye, LLC | $168.35 | 2025 | Iheezo, Triesence |
| Aerie Pharmaceuticals, INC. | $164.78 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $139.21 | 2023 | Eylea Hd |
| Alexion Pharmaceuticals, INC. | $100.07 | 2023 | Soliris |
| Coherus Oncology, INC. | $59.03 | 2022-2023 | |
| Bausch & Lomb Americas INC. | $56.75 | 2022-2025 | Xiidra |
| Horizon Therapeutics Plc | $53.02 | 2022-2023 | Tepezza |
| Kala Pharmaceuticals, INC. | $38.17 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $34.46 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $33.81 | 2021 | |
| Sun Pharmaceutical Industries INC. | $33.28 | 2021-2022 | |
| Mallinckrodt Enterprises LLC | $26.13 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $23.15 | 2024 | Xdemvy |
| Astellas Pharma US INC | $19.25 | 2025 | Izervay |
| Alimera Sciences, INC. | $15.48 | 2024 | Yutiq, Iluvien |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Stoller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.